Matthew Hein, U.S. Department of Commerce

Should I Pursue Emerging Medtech Markets?

By MedTech Intelligence Staff
No Comments
Matthew Hein, U.S. Department of Commerce

Many companies go for product approval in smaller markets first. Is that the right decision?

Global healthcare spending is roughly $7 trillion, according to Matthew Hein, International Trade Specialist for the U.S. Department of Commerce. Considering the market outside of the United States is about 25% larger, companies may have more success pursuing product approval in emerging markets—beyond China, India and Brazil—because the technologies may be more helpful for those patient populations and the regulatory burdens more manageable, suggests Hein in the following video, which was filmed during the MedTech Intelligence Global Regulatory conference last week.

 

 

About The Author

MedTech Intelligence

Leave a Reply

Your email address will not be published. Required fields are marked *